Barbara Palkovic1, Jennifer J Callison2, Vitaliy Marchenko2, Eckehard A E Stuth3, Edward J Zuperku4, Astrid G Stucke3. 1. From the Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin; the Faculty of Medicine, University of Osijek, Osijek, Croatia. 2. From the Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. From the Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin; Children's Wisconsin, Milwaukee, Wisconsin. 4. From the Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin; the Zablocki VA Medical Center, Milwaukee, Wisconsin.
Abstract
BACKGROUND: Recent studies showed partial reversal of opioid-induced respiratory depression in the pre-Bötzinger complex and the parabrachial nucleus/Kölliker-Fuse complex. The hypothesis for this study was that opioid antagonism in the parabrachial nucleus/Kölliker-Fuse complex plus pre-Bötzinger complex completely reverses respiratory depression from clinically relevant opioid concentrations. METHODS: Experiments were performed in 48 adult, artificially ventilated, decerebrate rabbits. The authors decreased baseline respiratory rate ~50% with intravenous, "analgesic" remifentanil infusion or produced apnea with remifentanil boluses and investigated the reversal with naloxone microinjections (1 mM, 700 nl) into the Kölliker-Fuse nucleus, parabrachial nucleus, and pre-Bötzinger complex. In another group of animals, naloxone was injected only into the pre-Bötzinger complex to determine whether prior parabrachial nucleus/Kölliker-Fuse complex injection impacted the naloxone effect. Last, the µ-opioid receptor agonist [d-Ala,2N-MePhe,4Gly-ol]-enkephalin (100 μM, 700 nl) was injected into the parabrachial nucleus/Kölliker-Fuse complex. The data are presented as medians (25 to 75%). RESULTS: Remifentanil infusion reduced the respiratory rate from 36 (31 to 40) to 16 (15 to 21) breaths/min. Naloxone microinjections into the bilateral Kölliker-Fuse nucleus, parabrachial nucleus, and pre-Bötzinger complex increased the rate to 17 (16 to 22, n = 19, P = 0.005), 23 (19 to 29, n = 19, P < 0.001), and 25 (22 to 28) breaths/min (n = 11, P < 0.001), respectively. Naloxone injection into the parabrachial nucleus/Kölliker-Fuse complex prevented apnea in 12 of 17 animals, increasing the respiratory rate to 10 (0 to 12) breaths/min (P < 0.001); subsequent pre-Bötzinger complex injection prevented apnea in all animals (13 [10 to 19] breaths/min, n = 12, P = 0.002). Naloxone injection into the pre-Bötzinger complex alone increased the respiratory rate to 21 (15 to 26) breaths/min during analgesic concentrations (n = 10, P = 0.008) but not during apnea (0 [0 to 0] breaths/min, n = 9, P = 0.500). [d-Ala,2N-MePhe,4Gly-ol]-enkephalin injection into the parabrachial nucleus/Kölliker-Fuse complex decreased respiratory rate to 3 (2 to 6) breaths/min. CONCLUSIONS: Opioid reversal in the parabrachial nucleus/Kölliker-Fuse complex plus pre-Bötzinger complex only partially reversed respiratory depression from analgesic and even less from "apneic" opioid doses. The lack of recovery pointed to opioid-induced depression of respiratory drive that determines the activity of these areas.
BACKGROUND: Recent studies showed partial reversal of opioid-induced respiratory depression in the pre-Bötzinger complex and the parabrachial nucleus/Kölliker-Fuse complex. The hypothesis for this study was that opioid antagonism in the parabrachial nucleus/Kölliker-Fuse complex plus pre-Bötzinger complex completely reverses respiratory depression from clinically relevant opioid concentrations. METHODS: Experiments were performed in 48 adult, artificially ventilated, decerebrate rabbits. The authors decreased baseline respiratory rate ~50% with intravenous, "analgesic" remifentanil infusion or produced apnea with remifentanil boluses and investigated the reversal with naloxone microinjections (1 mM, 700 nl) into the Kölliker-Fuse nucleus, parabrachial nucleus, and pre-Bötzinger complex. In another group of animals, naloxone was injected only into the pre-Bötzinger complex to determine whether prior parabrachial nucleus/Kölliker-Fuse complex injection impacted the naloxone effect. Last, the µ-opioid receptor agonist [d-Ala,2N-MePhe,4Gly-ol]-enkephalin (100 μM, 700 nl) was injected into the parabrachial nucleus/Kölliker-Fuse complex. The data are presented as medians (25 to 75%). RESULTS: Remifentanil infusion reduced the respiratory rate from 36 (31 to 40) to 16 (15 to 21) breaths/min. Naloxone microinjections into the bilateral Kölliker-Fuse nucleus, parabrachial nucleus, and pre-Bötzinger complex increased the rate to 17 (16 to 22, n = 19, P = 0.005), 23 (19 to 29, n = 19, P < 0.001), and 25 (22 to 28) breaths/min (n = 11, P < 0.001), respectively. Naloxone injection into the parabrachial nucleus/Kölliker-Fuse complex prevented apnea in 12 of 17 animals, increasing the respiratory rate to 10 (0 to 12) breaths/min (P < 0.001); subsequent pre-Bötzinger complex injection prevented apnea in all animals (13 [10 to 19] breaths/min, n = 12, P = 0.002). Naloxone injection into the pre-Bötzinger complex alone increased the respiratory rate to 21 (15 to 26) breaths/min during analgesic concentrations (n = 10, P = 0.008) but not during apnea (0 [0 to 0] breaths/min, n = 9, P = 0.500). [d-Ala,2N-MePhe,4Gly-ol]-enkephalin injection into the parabrachial nucleus/Kölliker-Fuse complex decreased respiratory rate to 3 (2 to 6) breaths/min. CONCLUSIONS: Opioid reversal in the parabrachial nucleus/Kölliker-Fuse complex plus pre-Bötzinger complex only partially reversed respiratory depression from analgesic and even less from "apneic" opioid doses. The lack of recovery pointed to opioid-induced depression of respiratory drive that determines the activity of these areas.
Authors: Denise R Cook-Snyder; Justin R Miller; Angela A Navarrete-Opazo; Jennifer J Callison; Robin C Peterson; Francis A Hopp; Eckehard A E Stuth; Edward J Zuperku; Astrid G Stucke Journal: Respir Physiol Neurobiol Date: 2018-11-28 Impact factor: 1.931
Authors: Angela A Navarrete-Opazo; Denise R Cook-Snyder; Justin R Miller; Jennifer J Callison; Nicole McCarthy; Barbara Palkovic; Eckehard A E Stuth; Edward J Zuperku; Astrid G Stucke Journal: Respir Physiol Neurobiol Date: 2020-02-06 Impact factor: 1.931
Authors: Justin R Miller; Edward J Zuperku; Eckehard A E Stuth; Anjishnu Banerjee; Francis A Hopp; Astrid G Stucke Journal: Anesthesiology Date: 2017-09 Impact factor: 7.892
Authors: Josiane N Silva; Elvis V Lucena; Talita M Silva; Rosélia S Damasceno; Ana C Takakura; Thiago S Moreira Journal: Neuroscience Date: 2016-04-26 Impact factor: 3.590
Authors: Barbara Palkovic; Denise Cook-Snyder; Jennifer J Callison; Thomas M Langer; Riley Nugent; Eckehard A E Stuth; Edward J Zuperku; Astrid G Stucke Journal: Respir Physiol Neurobiol Date: 2022-02-03 Impact factor: 1.931
Authors: Marieke Hyke Algera; Joseph F Cotten; Monique van Velzen; Marieke Niesters; Martijn Boon; Daniel S Shoham; Kaye E Dandrea; Rutger van der Schrier; Albert Dahan Journal: Pharmacol Res Perspect Date: 2022-06
Authors: Maia G Gumnit; Jyoti J Watters; Tracy L Baker; Sarah M Johnson; Stephen M Johnson Journal: Front Physiol Date: 2022-07-22 Impact factor: 4.755
Authors: Paulina M Getsy; Santhosh M Baby; Walter J May; James N Bates; Christopher R Ellis; Michael G Feasel; Christopher G Wilson; Tristan H J Lewis; Benjamin Gaston; Yee-Hsee Hsieh; Stephen J Lewis Journal: Front Pharmacol Date: 2022-09-28 Impact factor: 5.988